Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3
Status:
Completed
Trial end date:
2019-06-26
Target enrollment:
Participant gender:
Summary
Varying oral doses of Varenicline (VCN), starting with very low doses, will be administered
to participants with Parkinson's Disease (PD) or healthy controls without PD for several
days. Positron emission tomography (PET) scans after administration of VCN will be used to
determine the lowest oral dose of VCN producing an adequate brain level of VCN. These
experiments (1 & 2) will be used to determine an appropriate oral dose of VCN to administer
to PD participants for experiment 3 of the study (see NCT04403399).